The issuance of this patent adds to the company's intellectual property portfolio with 11 issued U.S. patents and 34 foreign equivalents. The company's second technology, Switch-Blocker, can be used for the detection of important rare genetic events in cancer and drug resistance. The intellectual property underlying the Primer-Switch and the Switch-Blocker technologies is jointly owned by Aegea and Biocept.

Under Aegea and Biocept's cross licensing agreement relating to the Primer-Switch and Switch-Blocker intellectual property, Aegea has exclusive rights in the field of infectious disease, and Biocept has certain rights within the field of clinical oncology. Aegea is the sole owner of its nine other issued U.S. patents and their foreign equivalents.

The Primer-Switch technology is used for the detection of rare genetic events, and to enhance performance and specificity of polymerase chain reaction amplification reactions and next-generation sequencing, which are widely used in molecular diagnostic testing, including COVID-19 testing, and hereditary disease testing.

Cellect secures stem cell-based therapy patent
Cellect Biotechnology has secured a European patent for its stem cell selection technology. The patent was also approved in Australia and Israel, according...

Bio-Rad wins appeal in 10x Genomics patent infringement ruling
Bio-Rad Laboratories said that the U.S. Court of Appeals for the Federal Circuit has affirmed a lower court ruling that 10x Genomics had willfully infringed...

MilliporeSigma granted foundational CRISPR-Cas9 U.S. patents
MilliporeSigma announced on May 11 that two of its CRISPR-Cas9-assisted genome-editing patents have been allowed in the U.S. The allowances cover cleavage...

ReForm gets patents for therapeutic protein formulations
ReForm Biologics has received a U.S. patent for therapeutic protein formulations that reduce protein aggregation and stabilize proteins during storage.

Enzychem files patent application for COVID-19 drug candidate
Enzychem Lifesciences has filed a provisional patent application with the U.S. Patent and Trademark Office to cover treating COVID-19 with its compound...